Skip to main content

Research Repository

Advanced Search

Clinically Translatable Transcrocetin Delivery Platform for Correction of Tumor Hypoxia and Enhancement of Radiation Therapy Effects

Diringer, Marie‐Charlotte; Coliat, Pierre; Mathieu, Clélia; Laurent, Nina; Mura, Carole; Banerjee, Mainak; Zhu, Chen; Grabowska, Anna; Ritchie, Alison; Clarke, Philip; Bernard, Alexandre; Vit, Claire; Burckel, Hélène; Noel, Georges; Harvey, Peter; Pivot, Xavier; Detappe, Alexandre

Clinically Translatable Transcrocetin Delivery Platform for Correction of Tumor Hypoxia and Enhancement of Radiation Therapy Effects Thumbnail


Authors

Marie‐Charlotte Diringer

Pierre Coliat

Clélia Mathieu

Nina Laurent

Carole Mura

Mainak Banerjee

Chen Zhu

Anna Grabowska

Alison Ritchie

Philip Clarke

Alexandre Bernard

Claire Vit

Hélène Burckel

Georges Noel

Xavier Pivot

Alexandre Detappe



Abstract

Improving the tumor reoxygenation to sensitize the tumor to radiation therapy is a cornerstone in radiation oncology. Here, the pre‐clinical development of a clinically transferable liposomal formulation encapsulating trans sodium crocetinate (NP TSC) is reported to improve oxygen diffusion through the tumor environment. Early pharmacokinetic analysis of the clinical trial of this molecule performed on 37 patients orient to define the optimal fixed dosage to use in a triple‐negative breast cancer model to validate the therapeutic combination of radiation therapy and NP TSC. Notably, it is reported that this formulation is non‐toxic in both humans and mice at the defined fixed concentration, provides a normalization of the tumor vasculature within 72 h window after systemic injection, leads to a transient increase (50% improvement) in the tumor oxygenation, and significantly improves the efficacy of both mono‐fractionated and fractionated radiation therapy treatment. Together, these findings support the introduction of a first‐in‐class therapeutic construct capable of tumor‐specific reoxygenation without associated toxicities.

Citation

Diringer, M., Coliat, P., Mathieu, C., Laurent, N., Mura, C., Banerjee, M., Zhu, C., Grabowska, A., Ritchie, A., Clarke, P., Bernard, A., Vit, C., Burckel, H., Noel, G., Harvey, P., Pivot, X., & Detappe, A. (2023). Clinically Translatable Transcrocetin Delivery Platform for Correction of Tumor Hypoxia and Enhancement of Radiation Therapy Effects. Small, 19(12), Article 2205961. https://doi.org/10.1002/smll.202205961

Journal Article Type Article
Acceptance Date Jan 1, 2023
Online Publication Date Jan 1, 2023
Publication Date Mar 22, 2023
Deposit Date Apr 17, 2023
Publicly Available Date Apr 18, 2023
Journal Small
Print ISSN 1613-6810
Electronic ISSN 1613-6829
Publisher Wiley
Peer Reviewed Peer Reviewed
Volume 19
Issue 12
Article Number 2205961
DOI https://doi.org/10.1002/smll.202205961
Keywords Drug delivery, liposome, oxygenation, trans sodium crocetinate
Public URL https://nottingham-repository.worktribe.com/output/15923861
Publisher URL https://onlinelibrary.wiley.com/doi/10.1002/smll.202205961
Additional Information Received: 2022-09-28; Published: 2023-01-01

Files

Clinically Translatable Transcrocetin Delivery Platform for Correction of Tumor Hypoxia and Enhancement of Radiation Therapy Effects (6.6 Mb)
PDF

Publisher Licence URL
https://creativecommons.org/licenses/by-nc/4.0/

Copyright Statement
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.





You might also like



Downloadable Citations